Therapeutic and Adverse Effects of Metformin in Diabetes: A Review Article
Life Sciences-Endocrinology
DOI:
https://doi.org/10.22376/ijlpr.2023.13.1.L261-272Keywords:
Metformin, Diabetes, effects, Obesity, Cardiovascular.Abstract
Metformin is the most often prescribed first-line oral antidiabetic. This review summarized the effects of Metformin on the body, its role in diabetes prevention and treatment, and the adverse effects of metformin administration. A PubMed search for metformin-related papers in diabetic patients was performed. We included articles on any metformin oral dosage in people with or without type 2 diabetes that reported favorable and unfavorable outcomes. Relevant studies from the references provided were reviewed. Metformin controls the blood glucose level by multiple mechanisms. These include increasing the cell sensitivity to insulin and reducing endogenous glucose secretion by the liver. Also, Metformin has been shown to assist in weight reduction in obese patients. Some early investigations showed that lifestyle changes and Metformin significantly reduced the incidence of diabetes in high-risk people, and lifestyle interventions were more effective than Metformin. Some trials indicated Metformin was not associated with any significant endangerment or advantage in terms of cardiovascular incidents. However, Metformin tended to be more effective in longer trials involving younger individuals regarding cardiovascular outcomes. The microvascular complication prevalence was insignificant between Metformin and other treatment interventions including placebo and lifestyle interventions. The gastrointestinal symptoms are common with metformin use as compared to placebo. Metformin increased the risk of lactic acidosis, especially in moderate and severe renal impairment settings, thus considered contraindicated. However, due to the low reported incidence of lactic acidosis associated with Metformin and the potential protective properties on the kidney, heart, and liver, it is advised to carefully balance the risk and benefits of Metformin when treating diabetes. In addition, Metformin has been shown to cause consequences other than gastrointestinal symptoms, such as vitamin B12 deficiency which can lead to hematologic issues, such as anaemia and peripheral neuropathy. Thus, periodic measurement of vitamin B12 for individuals treated with Metformin is recommended.
References
Thomas CC, Philipson LH. Update on diabetes classification. Med Clin North Am. 2015 Jan;99(1):1-16. doi: 10.1016/j.mcna.2014.08.015. PMID 25456640.
Nasri H, Rafieian-Kopaei M. Metformin: current knowledge. J Res Med Sci. 2014;19(7):658-64. PMID 25364368.
Effect of intensive blood-glucose control with Metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854-65. PMID 9742977.
Sung JY, Choi HC. Metformin-induced AMP-activated protein kinase activation regulates phenylephrine-mediated contraction of rat aorta. Biochem Biophys Res Commun. 2012;421(3):599-604. doi: 10.1016/j.bbrc.2012.04.052, PMID 22525678.
Seo-Mayer PW, Thulin G, Zhang L, Alves DS, Ardito T, Kashgarian M, et al. Preactivation of AMPK by Metformin may ameliorate the epithelial cell damage caused by renal ischemia. Am J Physiol Renal Physiol. 2011;301(6):F1346-57. doi: 10.1152/ajprenal.00420.2010, PMID 21849490.
Rösen P, Wiernsperger NF. Metformin delays the manifestation of diabetes and vascular dysfunction in Goto–Kakizaki rats by reduction of mitochondrial oxidative stress. Diabetes Metab Res Rev. 2006;22(4):323-30. doi: 10.1002/dmrr.623, PMID 16444763.
Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of Metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333(9):550-4. doi: 10.1056/NEJM199508313330903, PMID 7623903.
Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of Metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med. 1997;103(6):491-7. doi: 10.1016/s0002-9343(97)00254-4, PMID 9428832.
Kim YW, Kim JY, Park YH, Park SY, Won KC, Choi KH, et al. Metformin restores leptin sensitivity in high-fat-fed obese rats with leptin resistance. Diabetes. 2006;55(3):716-24. doi: 10.2337/diabetes.55.03.06.db05-0917, PMID 16505235.
Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or Metformin. N Engl J Med. 2002 Feb 7;346(6):393-403. doi: 10.1056/NEJMoa012512, PMID 11832527.
Harreiter J, Roden M. Diabetes mellitus – Definition, Klassifikation, Diagnose, Screening und Prävention (Update 2019) [Diabetes mellitus-Definition, classification, diagnosis, screening and prevention (Update 2019)]. Wien Klin Wochenschr. 2019 May;131(Suppl 1);Suppl 1:6-15. German.. doi: 10.1007/s00508-019-1450-4, PMID 30980151.
Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of Metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2011;13(3):221-8. doi: 10.1111/j.1463-1326.2010.01349.x, PMID 21205121.
Boussageon R, Supper I, Bejan-Angoulvant T, Kellou N, Cucherat M, Boissel JP, et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomized controlled trials. PLOS Med. 2012;9(4):e1001204. doi: 10.1371/journal.pmed.1001204, PMID 22509138.
Griffin SJ, Leaver JK, Irving GJ. Impact of Metformin on cardiovascular disease: a meta-analysis of randomized trials among people with type 2 diabetes. Diabetologia. 2017;60(9):1620-9. doi: 10.1007/s00125-017-4337-9, PMID 28770324.
Diabetes Prevention Program Research Group. Long-term effects of lifestyle intervention or Metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015;3(11):866-75. doi: 10.1016/S2213-8587(15)00291-0, PMID 26377054.
Diabetes Prevention Program Research Group. Long-term safety, tolerability, and weight loss associated with Metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care. 2012;35(4):731-7. doi: 10.2337/dc11-1299, PMID 22442396.
Bonnet F, Scheen A. Understanding and overcoming metformin gastrointestinal intolerance. Diabetes Obes Metab. 2017 Apr;19(4):473-81. doi: 10.1111/dom.12854. PMID 27987248.
DeFronzo R, Fleming GA, Chen K, Bicsak TA. Metformin-associated lactic acidosis: current perspectives on causes and risk. Metabolism. 2016 Feb;65(2):20-9. doi: 10.1016/j.metabol.2015.10.014. PMID 26773926.
Salvatore T, Pafundi PC, Marfella R, Sardu C, Rinaldi L, Monaco L et al. Metformin lactic acidosis: should we still be afraid? Diabetes Res Clin Pract. 2019 Nov;157:107879. doi: 10.1016/j.diabres.2019.107879. PMID 31618624.
Aroda VR, Edelstein SL, Goldberg RB, Knowler WC, Marcovina SM, Orchard TJ et al. Long-term metformin use and vitamin B12 deficiency in the diabetes prevention program outcomes study. J Clin Endocrinol Metab. 2016 Apr;101(4):1754-61. doi: 10.1210/jc.2015-3754. PMID 26900641.
Infante M, Leoni M, Caprio M, Fabbri A. Long-term metformin therapy and vitamin B12 deficiency: an association to bear in mind. World J Diabetes. 2021 Jul 15;12(7):916-31. doi: 10.4239/wjd.v12.i7.916, PMID 34326945.
Alharbi TJ, Tourkmani AM, Abdelhay O, Alkhashan HI, Al-Asmari AK, Bin Rsheed AM et al. The association of metformin use with vitamin B12 deficiency and peripheral neuropathy in Saudi individuals with type 2 diabetes mellitus. PLOS ONE. 2018 Oct 15;13(10):e0204420. doi: 10.1371/journal.pone.0204420, PMID 30321183.
Yang W, Cai X, Wu H, Ji L. Associations between metformin use and vitamin B
12 levels, anemia, and neuropathy in patients with diabetes: a meta-analysis. J Diabetes. 2019 Sep;11(9):729-43. doi: 10.1111/1753-0407.12900. PMID 30615306.
Herbert L, Ribar A, Mitchell S, Phillips C. Discovering metformin-induced vitamin B12 deficiency in patients with type 2 diabetes in primary care. J Am Assoc Nurse Pract. 2019 Oct 20;33(2):174-80. doi: 10.1097/JXX.0000000000000312, PMID 31651584.
Morley JE. The elderly Type 2 diabetic patient: special considerations. Diabet Med. 1998;15;Suppl 4:S41-6. doi: 10.1002/(sici)1096-9136(1998120)15:4+3.3.co;2-5, PMID 9868991.
Lalau JD, Race JM. Lactic acidosis in metformin therapy. Drugs. 1999;58;Suppl 1:55-60; discussion 75. doi: 10.2165/00003495-199958001-00013, PMID 10576527.
Andrès E, Noel E, Schlienger JL, Blicklé JF. Mild cobalamin deficiency associated with long-term metformin intake--reply. J Intern Med. 2004;255(2):302-3. doi: 10.1046/j.1365-2796.2003.01290.x, PMID 14746570.
Wulffelé MG, Kooy A, Lehert P, Bets D, Ogterop JC, Borger van der Burg B, et al. Effects of short-term treatment with Metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Intern Med. 2003;254(5):455-63. doi: 10.1046/j.1365-2796.2003.01213.x, PMID 14535967.
Runcie J. Folate deficiency in the elderly. In: Botez M, Reynolds E, editors. Folic acid in neurology, psychiatry and internal medicine. New York: Raven; 1979. p. 493-9.
Nexø E. Variation with age of reference values for P-cobalamins. Scand J Haematol. 1983;30(5):430-2. doi: 10.1111/j.1600-0609.1983.tb02530.x, PMID 6857150.
Gregorio F, Ambrosi F, Filipponi P, Manfrini S, Testa I. Is Metformin safe enough for ageing type 2 diabetic patients? Diabetes Metab. 1996;22(1):43-50. PMID 8697295.
Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with Metformin. N Engl J Med. 1998;338(4):265-6. doi: 10.1056/NEJM199801223380415, PMID 9441244.
Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med. 2003;163(4):427-36. doi: 10.1001/archinte.163.4.427, PMID 12588201.
Campbell IW, Howlett HC. Worldwide experience of Metformin as an effective glucose-lowering agent: a meta-analysis. Diabetes Metab Rev. 1995;11;Suppl 1:S57-62. doi: 10.1002/dmr.5610110509, PMID 8529486.
Effect of intensive blood-glucose control with Metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854-65 [published correction appears in Lancet. 1998 Nov 7;352(9139):1558. doi: 10.1016/S0140-6736(05)60377-7, PMID 9820340].
Bailey CJ. Biguanides and NIDDM. Diabetes Care. 1992;15(6):755-72. doi: 10.2337/diacare.15.6.755, PMID 1600835.
Lawson AA, Strong JA, Peattie P, Roscoe P, Gibson A. Comparison of fenfluramine and Metformin in treatment of obesity. Lancet. 1970;2(7670):437-41. doi: 10.1016/s0140-6736(70)90056-5, PMID 4195118.
Munro JF, MacCuish AC, Marshall A, Wilson EM, Duncan LJ. Weight-reducing effect of diguanides in obese non-diabetic women. Br Med J. 1969;2(5648):13-5. doi: 10.1136/bmj.2.5648.13, PMID 4887385.
Fontbonne A, André P, Eschwège EE. BIGPRO (biguanides and the prevention of the risk of obesity): study design. A randomized trial of Metformin versus placebo in the correction of the metabolic abnormalities associated with insulin resistance. Diabete Metab. 1991;17(1 Pt 2):249-54. PMID 1936485.
Fontbonne A, Charles MA, Juhan-Vague I, Bard JM, André P, Isnard F, et al. The effect of Metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO study Group. Diabetes Care. 1996;19(9):920-6. doi: 10.2337/diacare.19.9.920, PMID 8875083.
Charles MA, Morange P, Eschwège E, André P, Vague P, Juhan-Vague I. Effect of weight change and Metformin on fibrinolysis and the von Willebrand factor in obese non-diabetic subjects: the BIGPRO1 study. Biguanides and the prevention of the risk of obesity. Diabetes Care. 1998;21(11):1967-72. doi: 10.2337/diacare.21.11.1967, PMID 9802752.
Charles MA, Eschwège E, Grandmottet P, Isnard F, Cohen JM, Bensoussan JL, et al. Treatment with Metformin of non-diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial. Diabetes Metab Res Rev. 2000;16(1):2-7. doi: 10.1002/(sici)1520-7560(200001/02)16:1<2::aid-dmrr75>3.0.co;2-g, PMID 10707032.
Slama G. The potential of Metformin for diabetes prevention. Diabetes Metab. 2003;29(4 Pt 2):6S104-11. doi: 10.1016/s1262-3636(03)72794-3, PMID 14502107.
The Diabetes Prevention Program Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. The diabetes prevention program research Group. Diabetes Care. 2000;23(11):1619-29. doi: 10.2337/diacare.23.11.1619, PMID 11092283.
Freemark M, Bursey D. The effects of Metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics. 2001;107(4):E55. doi: 10.1542/peds.107.4.e55, PMID 11335776.
Kay JP, Alemzadeh R, Langley G, D'Angelo L, Smith P, Holshouser S. Beneficial effects of Metformin in normoglycemic morbidly obese adolescents. Metabolism. 2001;50(12):1457-61. doi: 10.1053/meta.2001.28078, PMID 11735093.
Oleandri SE, Maccario M, Rossetto R, Procopio M, Grottoli S, Avogadri E, et al. Three-month treatment with Metformin or dexfenfluramine does not modify the effects of diet on anthropometric and endocrine-metabolic parameters in abdominal obesity. J Endocrinol Invest. 1999;22(2):134-40. doi: 10.1007/BF03350893, PMID 10195381.
Gokcel A, Gumurdulu Y, Karakose H, Melek Ertorer E, Tanaci N, BascilTutuncu N, et al. Evaluation of the safety and efficacy of sibutramine, orlistat and Metformin in the treatment of obesity. Diabetes Obes Metab. 2002;4(1):49-55. doi: 10.1046/j.1463-1326.2002.00181.x, PMID 11874442.
Paolisso G, Amato L, Eccellente R, Gambardella A, Tagliamonte MR, Varricchio G, et al. Effect of Metformin on food intake in obese subjects. Eur J Clin Invest. 1998;28(6):441-6. doi: 10.1046/j.1365-2362.1998.00304.x, PMID 9693934.
Fruehwald-Schultes B, Oltmanns KM, Toschek B, Sopke S, Kern W, Born J, et al. Short-term treatment with Metformin decreases serum leptin concentration without affecting body weight and body fat content in normal-weight healthy men. Metabolism. 2002;51(4):531-6. doi: 10.1053/meta.2002.31332, PMID 11912566.
Kowalska I, Kinalski M, Straczkowski M, Wolczyski S, Kinalska I. Insulin, leptin, IGF-I and insulin-dependent protein concentrations after insulin-sensitizing therapy in obese women with polycystic ovary syndrome. Eur J Endocrinol. 2001;144(5):509-15. doi: 10.1530/eje.0.1440509, PMID 11331217.
Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E, et al. Effect of Metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese non-diabetic subjects. Diabetes Care. 2001;24(3):489-94. doi: 10.2337/diacare.24.3.489, PMID 11289473.
Barbieri RL, Makris A, Randall RW, Daniels G, Kistner RW, Ryan KJ. Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab. 1986;62(5):904-10. doi: 10.1210/jcem-62-5-904, PMID 3514651.
Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A. Therapeutic effects of Metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol. 1998;138(3):269-74. doi: 10.1530/eje.0.1380269, PMID 9539300.
Chou KH, von Eye Corleta H, Capp E, Spritzer PM. Clinical, metabolic and endocrine parameters in response to Metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial. Horm Metab Res. 2003;35(2):86-91. doi: 10.1055/s-2003-39056, PMID 12734787.
Morin-Papunen LC, Koivunen RM, Ruokonen A, Martikainen HK. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril. 1998;69(4):691-696. doi:10.1016/s0015-0282(98)00011-9
Ibáñez L, Valls C, Ferrer A, Ong K, Dunger DB, de Zegher F. Additive effects of insulin-sensitizing and anti-androgen treatment in young, non-obese women with hyperinsulinism, hyperandrogenism, dyslipidemia, and anovulation. J Clin Endocrinol Metab. 2002;87(6):2870-4. doi: 10.1210/jcem.87.6.8568, PMID 12050266.
Mitkov M, Pehlivanov B, Terzieva D. Combined use of Metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2005;118(2):209-13. doi: 10.1016/j.ejogrb.2004.06.035, PMID 15653205.
De Leo V, la Marca A, Ditto A, Morgante G, Cianci A. Effects of Metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. Fertil Steril. 1999;72(2):282-5. doi: 10.1016/s0015-0282(99)00208-3, PMID 10438996.
Malkawi HY, Qublan HS. The effect of metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene-resistant women with polycystic ovary syndrome. Saudi Med J. 2002;23(6):663-6. PMID 12070543.
Malkawi HY, Qublan HS, Hamaideh AH. Medical vs. surgical treatment for clomiphene citrate-resistant women with polycystic ovary syndrome. J Obstet Gynaecol. 2003;23(3):289-93. doi: 10.1080/01443610310000100123, PMID 12850864.
Ibáñez L, Valls C, Potau N, Marcos MV, de Zegher F. Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. J Clin Endocrinol Metab. 2000;85(10):3526-30. doi: 10.1210/jcem.85.10.6908, PMID 11061495.
Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril. 2000;73(6):1149-54. doi: 10.1016/s0015-0282(00)00501-x, PMID 10856473.
Eagleson CA, Bellows AB, Hu K, Gingrich MB, Marshall JC. Obese patients with polycystic ovary syndrome: evidence that Metformin does not restore sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by ovarian steroids. J Clin Endocrinol Metab. 2003;88(11):5158-62. doi: 10.1210/jc.2003-030167, PMID 14602743.
Fleming R, Harborne L, MacLaughlin DT, Ling D, Norman J, Sattar N, et al. Metformin reduces serum Mullerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment. Fertil Steril. 2005;83(1):130-6. doi: 10.1016/j.fertnstert.2004.05.098, PMID 15652898.
Ghazeeri G, Kutteh WH, Bryer-Ash M, Haas D, Ke RW. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril. 2003;79(3):562-6. doi: 10.1016/s0015-0282(02)04843-4, PMID 12620440.
Mick GJ, Wang X, Ling Fu C, McCormick KL. Inhibition of leptin secretion by insulin and Metformin in cultured rat adipose tissue. Biochim Biophys Acta. 2000;1502(3):426-32. doi: 10.1016/s0925-4439(00)00074-0. PMID 11068185.
Kumari AS, Haq A, Jayasundaram R, Abdel-Wareth LO, Al Haija SA, Alvares M. Metformin monotherapy in lean women with polycystic ovary syndrome. Reprod Biomed Online. 2005;10(1):100-4. doi: 10.1016/s1472-6483(10)60809-7, PMID 15705302.
Coetzee EJ, Jackson WP. Oral hypoglycaemics in the first trimester and fetal outcome. S Afr Med J. 1984;65(16):635-7. PMID 6369573.
Hellmuth E, Damm P, Mølsted-Pedersen L. Oral hypoglycaemic agents in 118 diabetic pregnancies. Diabet Med. 2000;17(7):507-11. doi: 10.1046/j.1464-5491.2000.00314.x, PMID 10972579.
Vanky E, Salvesen KA, Heimstad R, Fougner KJ, Romundstad P, Carlsen SM. Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study. Hum Reprod. 2004;19(8):1734-40. doi: 10.1093/humrep/deh347, PMID 15178665.
Glueck CJ, Wang P, Goldenberg N, Sieve L. Pregnancy loss, polycystic ovary syndrome, thrombophilia, hypofibrinolysis, enoxaparin, Metformin. Clin Appl Thromb Hemost. 2004;10(4):323-34. doi: 10.1177/107602960401000404, PMID 15497018.
Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R et al. Non-alcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917-23. doi: 10.1053/jhep.2003.50161, PMID 12668987.
Ludwig J, McGill DB, Lindor KD. Review: non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 1997;12(5):398-403. doi: 10.1111/j.1440-1746.1997.tb00450.x, PMID 9195388.
Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. association of non-alcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107(5):450-5. doi: 10.1016/s0002-9343(99)00271-5, PMID 10569299.
Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Non-alcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50(8):1844-50. doi: 10.2337/diabetes.50.8.1844, PMID 11473047.
Marchesini G, Forlani G. NASH: from liver diseases to metabolic disorders and back to clinical hepatology. Hepatology. 2002;35(2):497-9. doi: 10.1053/jhep.2002.31551, PMID 11826428.
Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet. 2001;358(9285):893-4. doi: 10.1016/s0140-6736(01)06042-1, PMID 11567710.
Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, et al. A randomized controlled trial of Metformin versus vitamin E or prescriptive diet in non-alcoholic fatty liver disease. Am J Gastroenterol. 2005;100(5):1082-90. doi: 10.1111/j.1572-0241.2005.41583.x, PMID 15842582.
Preiss D, Sattar N, Harborne L, Norman J, Fleming R. The effects of 8 months of Metformin on circulating GGT and ALT levels in obese women with polycystic ovarian syndrome. Int J Clin Pract. 2008;62(9):1337-1343. doi:10.1111/j.1742-1241.2008.01825.x
Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108(8):1167-74. doi: 10.1172/JCI13505, PMID 11602624.
Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med. 2000;6(9):998-1003. doi: 10.1038/79697, PMID 10973319.
Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353(9170):2093-9. doi: 10.1016/S0140-6736(98)08468-2, PMID 10382692.
Seli E, Duleba AJ. Treatment of PCOS with Metformin and other insulin-sensitizing agents. Curr Diab Rep. 2004;4(1):69-75. doi: 10.1007/s11892-004-0014-8, PMID 14764283.
Shobokshi A, Shaarawy M. Correction of insulin resistance and hyperandrogenism in polycystic ovary syndrome by combined rosiglitazone and clomiphene citrate therapy. J Soc Gynecol Investig. 2003;10(2):99-104. doi: 10.1016/s1071-5576(02)00260-5, PMID 12593999.
Boettcher E, Csako G, Pucino F, Wesley R, Loomba R. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2012;35(1):66-75. doi:10.1111/j.1365-2036.2011.04912.x
Vague P, Juhan-Vague I, Alessi MC, Badier C, Valadier J. Metformin decreases the high plasminogen activator inhibition capacity, splasma insulin and triglyceride levels in non-diabetic obese subjects. Thromb Haemost. 1987;57(3):326-8. doi: 10.1055/s-0038-1651126, PMID 3310318.
Giugliano D, De Rosa N, Di Maro G, Marfella R, Acampora R, Buoninconti R, et al. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care. 1993;16(10):1387-90. doi: 10.2337/diacare.16.10.1387, PMID 8269798.
Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, et al. The effect of Metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial. Ann Intern Med. 2005;142(8):611-9. doi: 10.7326/0003-4819-142-8-200504190-00009, PMID 15838067.
Cleeman JI, Lenfant C. The National Cholesterol Education Program: progress and prospects. JAMA. 1998;280(24):2099-104. doi: 10.1001/jama.280.24.2099, PMID 9875878.
Lim SC, Tai ES, Tan BY, Chew SK, Tan CE. Cardiovascular risk profile in individuals with borderline glycemia: the effect of the 1997 American Diabetes Association diagnostic criteria and the 1998 World Health Organization Provisional Report. Diabetes Care. 2000;23(3):278-82. doi: 10.2337/diacare.23.3.278, PMID 10868851.
Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334(9):574-9. doi: 10.1056/NEJM199602293340906, PMID 8569826.
Cusi K, DeFronzo RA. Metformin: a review of its metabolic effects. Diabetes Rev. 1998 Jan 1;6(2):89-131.
Wiernsperger NF, Bailey CJ. The antihyperglycaemic effect of Metformin: therapeutic and cellular mechanisms. Drugs. 1999;58;Suppl 1:31-9; discussion 75. doi: 10.2165/00003495-199958001-00009, PMID 10576523.
Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, et al. mechanism by which Metformin reduces glucose production in type 2 diabetes. Diabetes. 2000;49(12):2063-9. doi: 10.2337/diabetes.49.12.2063, PMID 11118008.
Perriello G, Misericordia P, Volpi E, Santucci A, Santucci C, Ferrannini E et al. Acute antihyperglycemic mechanisms of Metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes. 1994;43(7):920-8. doi: 10.2337/diab.43.7.920, PMID 8013758.
Large V, Beylot M. Modifications of citric acid cycle activity and gluconeogenesis in streptozotocin-induced diabetes and effects of Metformin. Diabetes. 1999;48(6):1251-7. doi: 10.2337/diabetes.48.6.1251, PMID 10342812.
Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, et al. efficacy and metabolic effects of Metformin and troglitazone in type II diabetes mellitus. N Engl J Med. 1998;338(13):867-72. doi: 10.1056/NEJM199803263381303, PMID 9516221.
Jeng CY, Sheu WH, Fuh MM, Chen YD, Reaven GM. Relationship between hepatic glucose production and fasting plasma glucose concentration in patients with NIDDM. Diabetes. 1994;43(12):1440-4. doi: 10.2337/diab.43.12.1440, PMID 7958496.
Radziuk J, Zhang Z, Wiernsperger N, Pye S. Effects of Metformin on lactate uptake and gluconeogenesis in the perfused rat liver. Diabetes. 1997;46(9):1406-13. doi: 10.2337/diab.46.9.1406, PMID 9287039.
Argaud D, Roth H, Wiernsperger N, Leverve XM. Metformin decreases gluconeogenesis by enhancing the pyruvate kinase flux in isolated rat hepatocytes. Eur J Biochem. 1993;213(3):1341-8. doi: 10.1111/j.1432-1033.1993.tb17886.x, PMID 8504825.
Dominguez LJ, Davidoff AJ, Srinivas PR, Standley PR, Walsh MF, Sowers JR. Effects of Metformin on tyrosine kinase activity, glucose transport, and intracellular calcium in rat vascular smooth muscle. Endocrinology. 1996;137(1):113-21. doi: 10.1210/endo.137.1.8536601, PMID 8536601.
Yki-Järvinen H, Nikkilä K, Mäkimattila S. Metformin prevents weight gain by reducing dietary intake during insulin therapy in patients with type 2 diabetes mellitus. Drugs. 1999;58;Suppl 1:53-4; discussion 75. doi: 10.2165/00003495-199958001-00012, PMID 10576526.
Ebert BL, Firth JD, Ratcliffe PJ. Hypoxia and mitochondrial inhibitors regulate expression of glucose transporter-1 via distinct cis-acting sequences. J Biol Chem. 1995;270(49):29083-9. doi: 10.1074/jbc.270.49.29083, PMID 7493931.
Davidoff F, Bertolini D, Haas D. Enhancement of the mitochondrial Ca2+ uptake rate by phenethylbiguanide and other organic cations with hypoglycemic activity. Diabetes. 1978;27(7):757-65. doi: 10.2337/diab.27.7.757, PMID 658623.
Davidoff F, Carr S. Calcium-like action of phenethylbiguanide and related compounds: inhibition of pyruvate kinase. Proc Natl Acad Sci U S A. 1972;69(7):1957-61. doi: 10.1073/pnas.69.7.1957, PMID 4505673.
Kozka IJ, Holman GD. Metformin blocks downregulation of cell surface GLUT4 caused by chronic insulin treatment of rat adipocytes. Diabetes. 1993;42(8):1159-65. doi: 10.2337/diab.42.8.1159, PMID 8325447.
Klip A, Gumà A, Ramlal T, Bilan PJ, Lam L, Leiter LA. Stimulation of hexose transport by Metformin in L6 muscle cells in culture. Endocrinology. 1992;130(5):2535-44. doi: 10.1210/endo.130.5.1572281, PMID 1572281.
Hundal HS, Ramlal T, Reyes R, Leiter LA, Klip A. Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in L6 muscle cells. Endocrinology. 1992;131(3):1165-73. doi: 10.1210/endo.131.3.1505458, PMID 1505458.
Stith BJ, Goalstone ML, Espinoza R, Mossel C, Roberts D, Wiernsperger N. The antidiabetic drug metformin elevates receptor tyrosine kinase activity and inositol 1,4,5-trisphosphate mass in Xenopus oocytes. Endocrinology. 1996;137(7):2990-9. doi: 10.1210/endo.137.7.8770923, PMID 8770923.
Shulman GI. Cellular mechanisms of insulin resistance in humans. Am J Cardiol. 1999;84(1):3-10. doi: 10.1016/S0002-9149(99)00350-1.
Clore JN, Glickman PS, Nestler JE, Blackard WG. In vivo evidence for hepatic autoregulation during FFA-stimulated gluconeogenesis in normal humans. Am J Physiol. 1991;261(4 Pt 1):E425-9. doi: 10.1152/ajpendo.1991.261.4.E425, PMID 1928334.
Wilcock C, Bailey CJ. Reconsideration of inhibitory effect of Metformin on intestinal glucose absorption. J Pharm Pharmacol. 1991;43(2):120-1. doi: 10.1111/j.2042-7158.1991.tb06645.x, PMID 1672896.
Kelley DE, Mandarino LJ. Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes. 2000;49(5):677-83. doi: 10.2337/diabetes.49.5.677, PMID 10905472.
Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline GW, et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest. 1999;103(2):253-9. doi: 10.1172/JCI5001, PMID 9916137.
Patanè G, Piro S, Rabuazzo AM, Anello M, Vigneri R, Purrello F. Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells. Diabetes. 2000;49(5):735-40. doi: 10.2337/diabetes.49.5.735, PMID 10905481.
DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131(4):281-303. doi: 10.7326/0003-4819-131-4-199908170-00008, PMID 10454950.
Wilcock C, Bailey CJ. Accumulation of Metformin by tissues of the normal and diabetic mouse. Xenobiotica. 1994;24(1):49-57. doi: 10.3109/00498259409043220, PMID 8165821.
Ikeda T, Iwata K, Murakami H. Inhibitory effect of Metformin on intestinal glucose absorption in the perfused rat intestine. Biochem Pharmacol. 2000;59(7):887-90. doi: 10.1016/s0006-2952(99)00396-2, PMID 10718348.
Scarpello JH, Howlett HC. Metformin therapy and clinical uses. Diab Vasc Dis Res. 2008;5(3):157-67. doi: 10.3132/dvdr.2008.027, PMID 18777488.
Emslie-Smith AM, Boyle DI, Evans JM, Sullivan F, Morris AD, DARTS/MEMO Collaboration. Contraindications to metformin therapy in patients with Type 2 diabetes--a population-based study of adherence to prescribing guidelines. Diabet Med. 2001;18(6):483-8. doi: 10.1046/j.1464-5491.2001.00509.x, PMID 11472468.
Rakovac I, Jeitler K, Gfrerer RJ, Habacher W, Seereiner S, Mrak P, et al. Patients with Type 2 diabetes treated with Metformin: prevalence of contraindications and their correlation with discontinuation. Diabet Med. 2005;22(5):662-4. doi: 10.1111/j.1464-5491.2005.01478.x, PMID 15842528.
Sulkin TV, Bosman D, Krentz AJ. Contraindications to metformin therapy in patients with NIDDM. Diabetes Care. 1997;20(6):925-8. doi: 10.2337/diacare.20.6.925, PMID 9167101.
Scheen AJ. Clinical pharmacokinetics of Metformin. Clin Pharmacokinet. 1996;30(5):359-71. doi: 10.2165/00003088-199630050-00003, PMID 8743335.
DeFronzo RA, Goodman AM. Efficacy of Metformin in patients with non-insulin-dependent diabetes mellitus. The multicenter metformin study Group. N Engl J Med. 1995;333(9):541-9. doi: 10.1056/NEJM199508313330902, PMID 7623902.
Lalau JD, Andrejak M, Morinière P, Coevoet B, Debussche X, Westeel PF, et al. Hemodialysis in the treatment of lactic acidosis in diabetics treated by Metformin: a study of metformin elimination. Int J Clin Pharmacol Ther Toxicol. 1989;27(6):285-8. PMID 2500402.
Published
How to Cite
Issue
Section
Copyright (c) 2022 Abdulaziz Mohammed Alatawi, Afaf Fayez Albogami, Sarah Salem Aldharman, Salwa Mohammed Majrashi, Ruba Saleh Alghamdi, Nawari Essa Boobaid, Hyder Osman Mirghani Mohamed
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
